K2 Therapeutics raises $50.0M Seed (Singapore, Aug 2026)
$50.0M
US$50 million seed roundGenerated social card
Headline
Singapore-based biotech K2 Therapeutics secures US$50 million seed round; appoints Huang Ying as CEO - The Business Times
About
K2 Therapeutics is a Singapore-based biotech company focused on developing innovative therapies. The company has recently secured a significant seed funding round to advance its research and development efforts. This funding will support their mission to create impactful solutions in the healthcare sector.
Article summary
Singapore-based biotech K2 Therapeutics secures US$50 million seed round; appoints Huang Ying as CEO The Business Times
Founder
Huang Ying
CEO
Investors